Efmarodocokin alfa for COVID-19: real-time analysis

Download Image

Post

c19early.org

Efmarodocokin alfa for COVID-19

1 study with 266 patients

Serious outcome risk

Efmarodocokin Alfa

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Efmarodocokin alfa studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−15%

Mortality (1)−15%

RCTs (1)−15%

Late (1)−15%

00.511.5+

← Efmarodocokin
Alfa reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Nov 14 2022	Waters et al., Critical Care Medicine, doi:10.1097/CCM.0000000000005716	Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial
Nov 14 2022	15% higher mortality (p=0.67) and 13% improved recovery (p=0.35). RCT 396 hospitalized patients with severe COVID-19 pneumonia showing no significant difference in time to recovery with astegolimab (IL-33 receptor blocker) or efmarodocokin alfa (IL-22 pathway activator). Median time to recovery was 11 d..